IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Spectrum of Epstein-Barr Virus-Associated Diseases in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
Xuan, Li1; Jiang, Xinmiao1; Sun, Jing1; Zhang, Yu1; Huang, Fen1; Fan, Zhiping1; Guo, Xutao1; Dai, Min1; Liu, Can1; Yu, Guopan1; Zhang, Xian1; Wu, Meiqing1; Huang, Xiaojun2; Liu, Qifa1
关键词Spectrum Epstein-barr Virus-associated Disease Rituximab Allogeneic Hematopoietic Stem Cell Transplantation
刊名TRANSPLANTATION
2013-09-01
DOI10.1097/TP.0b013e31829d38af
96期:6页:560-566
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Immunology ; Surgery ; Transplantation
研究领域[WOS]Immunology ; Surgery ; Transplantation
关键词[WOS]POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE ; HIGH-RISK PATIENTS ; HEMATOLOGICAL MALIGNANCIES ; DISORDERS PTLD ; RITUXIMAB ; INFECTIONS ; THERAPY ; CHEMOTHERAPY ; LYMPHOMA ; ANTIBODY
英文摘要

Background. Epstein-Barr virus (EBV) infection may result in a spectrum of diseases in recipients of transplant. The aim of this study is to investigate the incidence, clinical characteristics, and prognosis of the spectrum of EBV-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods. A total of 263 recipients undergoing allo-HSCT were prospectively enrolled. The blood EBV-DNA loads were regularly monitored by quantitative real-time polymerase chain reaction.

Results. The 3-year cumulative incidence of total EBV-associated diseases, posttransplantation lymphoproliferative diseases (PTLD), EBV fever, and EBV end-organ diseases (pneumonia, encephalitis/myelitis, and hepatitis) were 15.6%+/- 2.5%, 9.9%+/- 2.0%, 3.3%+/- 1.3%, and 3.3%+/- 1.2% (2.2%+/- 1.0%, 1.6%+/- 0.8%, and 0.9%+/- 0.6%), respectively. Fever was the most common symptom of EBV-associated diseases. Patients with PTLD had better response rate to rituximab-based treatments compared with those with EBV end-organ diseases (including PTLD accompanied by EBV end-organ diseases) (P=0.014). The 3-year overall survival was 37.3%+/- 13.7%, 100.0%, and 0.0%+/- 0.0% in patients with PTLD, EBV fever, and EBV end-organ diseases (P=0.001).

Conclusions. EBV-associated diseases other than PTLD are not rare in the recipients of allo-HSCT. The clinical manifestations of EBV end-organ diseases are similar to PTLD. EBV end-organ diseases had poorer response to rituximab-based therapy compared with PTLD.

语种英语
WOS记录号WOS:000330383900014
项目编号2011AA020105 ; 201202017 ; 81000231 ; 81270647 ; 81200388 ; 30971300 ; 2009A030200007 ; 2012B031800403 ; A2010010 ; 10451008004004158
资助机构National High Technology Research and Development Program of China (863 Program) ; National Public Health Grand Research Foundation ; National Natural Science Foundation of China ; Science and Technology Project of Guangdong Province of China ; Medical Scientific Research Foundation of Guangdong Province ; Guangdong Natural Science Foundation
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52785
专题北京大学第二临床医学院_血液科
作者单位1.Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
2.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Xuan, Li,Jiang, Xinmiao,Sun, Jing,et al. Spectrum of Epstein-Barr Virus-Associated Diseases in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation[J]. TRANSPLANTATION,2013,96(6):560-566.
APA Xuan, Li.,Jiang, Xinmiao.,Sun, Jing.,Zhang, Yu.,Huang, Fen.,...&Liu, Qifa.(2013).Spectrum of Epstein-Barr Virus-Associated Diseases in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.TRANSPLANTATION,96(6),560-566.
MLA Xuan, Li,et al."Spectrum of Epstein-Barr Virus-Associated Diseases in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation".TRANSPLANTATION 96.6(2013):560-566.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xuan, Li]的文章
[Jiang, Xinmiao]的文章
[Sun, Jing]的文章
百度学术
百度学术中相似的文章
[Xuan, Li]的文章
[Jiang, Xinmiao]的文章
[Sun, Jing]的文章
必应学术
必应学术中相似的文章
[Xuan, Li]的文章
[Jiang, Xinmiao]的文章
[Sun, Jing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。